Holen Sie sich die Stockscreener-App
8.57
0.12%
-0.010
Schlusskurs vom Vortag:
$8.58
Offen:
$8.57
24-Stunden-Volumen:
522.28K
Relative Volume:
0.64
Marktkapitalisierung:
$389.41M
Einnahmen:
$84.82M
Nettoeinkommen (Verlust:
$-21.43M
KGV:
-17.49
EPS:
-0.49
Netto-Cashflow:
$-27.23M
1W Leistung:
+0.35%
1M Leistung:
+104.53%
6M Leistung:
+72.78%
1J Leistung:
-40.32%
1-Tages-Spanne:
$8.56
$8.58
1-Wochen-Bereich:
$8.54
$8.58
52-Wochen-Spanne:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Firmenname
Y Mabs Therapeutics Inc
Sektor
Branche
Telefon
646-885-8505
Adresse
202 CARNEGIE CENTER, PRINCETON, NY
Vergleichen Sie YMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
8.57 | 388.95M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Eingeleitet | Truist | Buy |
| 2023-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-04-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-27 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-12-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-10-31 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-03 | Fortgesetzt | Guggenheim | Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-05-01 | Eingeleitet | Janney | Buy |
| 2020-04-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Eingeleitet | Wedbush | Outperform |
| 2019-04-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-10-16 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
Is Y mAbs Therapeutics Inc. stock risky to hold nowMarket Weekly Review & Accurate Buy Signal Notifications - khodrobank.com
Sector ETF performance correlation with Y mAbs Therapeutics Inc.Market Trend Report & Reliable Price Breakout Alerts - Newser
How to escape a deep drawdown in Y mAbs Therapeutics Inc.Market Trend Review & Weekly Hot Stock Watchlists - Newser
Published on: 2025-09-04 23:05:35 - Newser
Can Y mAbs Therapeutics Inc. disrupt its industryEarnings Recap Report & AI Enhanced Trading Signals - khodrobank.com
Custom strategy builders for tracking Y mAbs Therapeutics Inc.Breakout Watch & Daily Chart Pattern Signal Reports - Newser
Exit strategy if you’re trapped in Y mAbs Therapeutics Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - Newser
Can volume confirm reversal in Y mAbs Therapeutics Inc.July 2025 PreEarnings & Accurate Intraday Trade Tips - Newser
Intraday pattern recognizer results for Y mAbs Therapeutics Inc.Trade Risk Summary & Weekly High Potential Alerts - Newser
Is Y mAbs Therapeutics Inc. impacted by rising ratesGlobal Markets & Trade Opportunity Analysis - khodrobank.com
Will Y mAbs Therapeutics Inc. stock go up soonBull Run & Daily Stock Momentum Reports - Newser
Detecting support and resistance levels for Y mAbs Therapeutics Inc.Dip Buying & Stepwise Trade Signal Implementation - Newser
Signal strength of Y mAbs Therapeutics Inc. stock in tech scannersWeekly Market Report & Weekly High Conviction Trade Ideas - Newser
Is Y mAbs Therapeutics Inc. trading at a discountJuly 2025 Movers & Fast Gaining Stock Strategy Reports - khodrobank.com
Tools to monitor Y mAbs Therapeutics Inc. recovery probabilityTrade Risk Assessment & Free Daily Entry Point Trade Alerts - Newser
Real time breakdown of Y mAbs Therapeutics Inc. stock performanceJuly 2025 Intraday Action & Long-Term Investment Growth Plans - Newser
Custom watchlist performance reports with Y mAbs Therapeutics Inc.July 2025 Levels & Safe Capital Investment Plans - Newser
Does Y mAbs Therapeutics Inc. fit your quant trading modelJuly 2025 Setups & Safe Swing Trade Setup Alerts - Newser
Chart based exit strategy for Y mAbs Therapeutics Inc.Trade Risk Summary & Detailed Earnings Play Alerts - Newser
Aug Big Picture: Is Y mAbs Therapeutics Inc. impacted by rising ratesMarket Weekly Review & High Conviction Buy Zone Alerts - خودرو بانک
Can Y mAbs Therapeutics Inc. navigate macro headwindsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - khodrobank.com
What is the long term forecast for Y mAbs Therapeutics Inc. stockJuly 2025 Weekly Recap & Weekly Top Stock Performers List - خودرو بانک
Is Y mAbs Therapeutics Inc. forming bullish engulfing patternsEarnings Overview Report & Growth Focused Stock Reports - khodrobank.com
Can Y mAbs Therapeutics Inc. stock double in the next yearQuarterly Earnings Summary & High Accuracy Swing Entry Alerts - khodrobank.com
Y mAbs Therapeutics Inc. stock retracement – recovery analysis2025 Market WrapUp & Verified Momentum Stock Watchlist - Newser
Y mAbs Therapeutics Inc. stock volume spike explainedPortfolio Value Report & AI Enhanced Trading Alerts - Newser
How to use Fibonacci retracement on Y mAbs Therapeutics Inc.Rate Hike & Precise Swing Trade Entry Alerts - Newser
Is Y mAbs Therapeutics Inc. stock a hidden gem2025 Price Action Summary & Low Drawdown Momentum Ideas - khodrobank.com
Can Y mAbs Therapeutics Inc. scale operations efficiently2025 Volatility Report & Stepwise Trade Execution Plans - khodrobank.com
Can Y mAbs Therapeutics Inc. stock outperform in a bear marketTrade Volume Report & Long Hold Capital Preservation Plans - khodrobank.com
Can Y mAbs Therapeutics Inc. continue delivering strong returns2025 Bull vs Bear & Low Volatility Stock Recommendations - khodrobank.com
Using R and stats models for Y mAbs Therapeutics Inc. forecastingWeekly Trend Recap & Reliable Price Breakout Signals - Newser
Can Y mAbs Therapeutics Inc. outperform in the next rallyRecession Risk & AI Powered Market Entry Ideas - khodrobank.com
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy? - sharewise.com
Chart based analysis of Y mAbs Therapeutics Inc. trends2025 Market Trends & Real-Time Buy Zone Alerts - Newser
What institutional flow reveals about Y mAbs Therapeutics Inc.Earnings Risk Report & Verified Swing Trading Watchlists - Newser
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? - MSN
Finanzdaten der Y Mabs Therapeutics Inc-Aktie (YMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Y Mabs Therapeutics Inc-Aktie (YMAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rossi Michael J | PRESIDENT & CEO |
Mar 07 '25 |
Sale |
5.20 |
3,917 |
20,368 |
137,083 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):